URGN UroGen Pharma (URGN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001668243
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
102
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · no price filed
What the filings say about URGN
Insiders, 180 days
-$4.2M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.1M
4 notices
UroGen Pharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, UroGen Pharma Ltd. insiders sold a net $4.2M of stock across 68 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Oct 8, 2025.
- The trade is 48.3% of the 4,561 shares held after it.
- 2 other insiders sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Degnan Chris sold about $80.8K of URGN on Oct 8, 2026; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Feb 3, 2026.
- The trade is 2.9% of the 53,141 shares held after it.
- 2 other insiders sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Smith Jason Drew sold about $64.6K of URGN on Sep 8, 2026; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.Context
- 38 earlier Form 4 trades (code P or S) here by this insider (1 buy, 37 sales), the last on Aug 20, 2026.
- The trade is 1.5% of the 59,882 shares held after it.
- 2 other insiders sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Schoenberg Mark sold about $37.4K of URGN on Sep 8, 2026; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.Context
- 37 earlier Form 4 trades (code P or S) here by this insider (1 buy, 36 sales), the last on Jul 9, 2026.
- The trade is 102.7% of the 59,086 shares held after it.
- 1 other insider sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Schoenberg Mark sold about $2.9M of URGN on Aug 20, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 102 funds added in the latest 13F quarter.Context
- 36 earlier Form 4 trades (code P or S) here by this insider (1 buy, 35 sales), the last on Jun 22, 2026.
- The trade is 8.3% of the 119,763 shares held after it.
- No other insider sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Schoenberg Mark sold about $400.0K of URGN on Jul 9, 2026, the largest insider sale at the company since 2022; 102 funds added in the latest 13F quarter.68 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$4.2M over 180 days
-$3.0M over 90 days
below 77% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
102 funds bought in last quarter
more than 69% of Pharma & Biotech
Revenue
+21.4% year over year
more than 68% of Pharma & Biotech
Margin
-139.8% net margin
below 61% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.9% of the float short (float per yahoo 2026-10-27) · 4.9 days to cover · settled 2026-10-15
more than 77% of Pharma & Biotech
What changed in the last 30 days
Oct 9Officer Christopher Degnan filed to sell $89.6K by Oct 8 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 9Chief Financial Officer Degnan Chris sold $80.8K (Oct 8)
Watch URGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+95.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns URGN: institutional holders (13F)
13F holdings, latest reported quarter
4,543,895 sh
$167.2M
3,201,461 sh
$117.8M
2,576,363 sh
$94.8M
2,434,207 sh
$89.6M
2,199,652 sh
$80.9M
Congress trades in URGN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
URGN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Christopher Degnan
Filed 2026-10-09
$89.6K
Mark Schoenberg
Filed 2026-09-09
$38.4K
Jason Smith
Filed 2026-09-09
$67.0K
Schoenberg Mark
Filed 2026-08-20
$2.9M
Schoenberg Mark
Filed 2026-07-09
$400.0K
URGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global Small Cap Fund
$499.9K position · as of 2026-05-31
0.8%
Small Cap Growth Fund
$33.5M position · as of 2026-07-31
0.6%
Clearwater Select Equity Fund
$2.3M position · as of 2026-06-30
0.4%
M Capital Appreciation Fund
$1.4M position · as of 2026-06-30
0.4%
VANGUARD EXPLORER VALUE FUND
$5.3M position · as of 2026-05-31
0.4%
American Century Small Cap Growth Insights ETF
$55.5K position · as of 2026-05-31
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
5
Phase 3
2 active
2
Not applicable
1 active
What changed recently
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk No
2026-10-23 · Active Not Recruiting → Completed
Phase 3
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC
2026-09-30 · Completion moved 2026-04 → 2027-10
,
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Elizabeth Barrett
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.3M
$11.8M
$1.2M
+164%
n/a
2024
$4.1M
$1.9M
$1.2M
+20%
n/a
2023
$4.6M
$6.3M
$1.4M
+69%
n/a
2022
$1.9M
$1.8M
$832.1K
-7%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.2M sold by insiders over 180 days, 102 funds added last quarter, $3.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
URGN financials
Revenue growth
+21.4%
XBRL, annual
Net margin
-139.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$188.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM URGN
| FY Dec 2025 | $109.8M |
| FY Dec 2024 | $90.4M |
| FY Dec 2023 | $82.7M |
| FY Dec 2022 | $64.4M |
| FY Dec 2021 | $48.0M |
| Jun 2026 | $72.5M |
| Mar 2026 | $51.0M |
| Dec 2025 | $37.8M |
| Sep 2025 | $27.5M |
| Jun 2025 | $24.2M |
| Mar 2025 | $20.3M |
| Dec 2024 | $24.6M |
| Sep 2024 | $25.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-51.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM URGN
| FY Dec 2025 | -139.8% |
| FY Dec 2024 | -140.4% |
| FY Dec 2023 | -123.6% |
| FY Dec 2022 | -170.6% |
| FY Dec 2021 | -230.7% |
| Jun 2026 | -19.8% |
| Mar 2026 | -46.3% |
| Dec 2025 | -69.7% |
| Sep 2025 | -121.3% |
| Jun 2025 | -206.2% |
| Mar 2025 | -216.5% |
| Dec 2024 | -152.7% |
| Sep 2024 | -93.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$159.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM URGN
| FY Dec 2025 | -$162.7M |
| FY Dec 2024 | -$97.1M |
| FY Dec 2023 | -$76.6M |
| FY Dec 2022 | -$87.8M |
| FY Dec 2021 | -$85.6M |
| Jun 2026 | -$33.1M |
| Mar 2026 | -$45.4M |
| Dec 2025 | -$38.3M |
| Sep 2025 | -$42.4M |
| Jun 2025 | -$40.0M |
| Mar 2025 | -$42.1M |
| Dec 2024 | -$13.7M |
| Sep 2024 | -$27.8M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity URGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.00x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 4.77x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.84x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt URGN
| FY Dec 2025 | -1.33x |
| FY Dec 2024 | -0.79x |
| FY Dec 2023 | -0.77x |
| FY Dec 2022 | -0.90x |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.84x |
| Mar 2026 | -0.87x |
| Dec 2025 | -1.33x |
| Sep 2025 | -1.13x |
| Jun 2025 | -1.01x |
| Mar 2025 | -0.88x |
| Dec 2024 | -0.79x |
| Sep 2024 | -0.79x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity URGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -211.6% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-42.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets URGN
| FY Dec 2025 | -63.1% |
| FY Dec 2024 | -54.7% |
| FY Dec 2023 | -65.1% |
| FY Dec 2022 | -86.0% |
| FY Dec 2021 | -91.7% |
| Jun 2026 | -42.3% |
| Mar 2026 | -53.2% |
| Dec 2025 | -63.1% |
| Sep 2025 | -67.6% |
| Jun 2025 | -63.2% |
| Mar 2025 | -61.8% |
| Dec 2024 | -54.7% |
| Sep 2024 | -46.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital URGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-37.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed URGN
| FY Dec 2025 | -63.4% |
| FY Dec 2024 | -50.0% |
| FY Dec 2023 | -50.6% |
| FY Dec 2022 | -75.6% |
| FY Dec 2021 | -93.3% |
| Jun 2026 | -37.9% |
| Mar 2026 | -53.0% |
| Dec 2025 | -63.4% |
| Sep 2025 | -64.8% |
| Jun 2025 | -60.5% |
| Mar 2025 | -56.8% |
| Dec 2024 | -50.0% |
| Sep 2024 | -38.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing URGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.8B
market value at close 2026-10-27 on 2026-07-28 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value URGN
| FY Dec 2025 | $1.1B |
| FY Dec 2024 | $399.2M |
| FY Dec 2023 | $466.5M |
| FY Dec 2022 | $246.9M |
| FY Dec 2021 | $168.9M |
| Jun 2026 | $1.9B |
| Mar 2026 | $954.9M |
| Dec 2025 | $1.1B |
| Sep 2025 | $955.0M |
| Jun 2025 | $661.3M |
| Mar 2025 | $527.9M |
| Dec 2024 | $399.2M |
| Sep 2024 | $531.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-9.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield URGN
| FY Dec 2025 | -14.8% |
| FY Dec 2024 | -21.6% |
| FY Dec 2023 | -16.5% |
| FY Dec 2022 | -42.9% |
| FY Dec 2021 | -40.2% |
| Jun 2026 | -8.9% |
| Mar 2026 | -19.0% |
| Dec 2025 | -14.8% |
| Sep 2025 | -15.0% |
| Jun 2025 | -19.6% |
| Mar 2025 | -21.1% |
| Dec 2024 | -21.6% |
| Sep 2024 | -18.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing URGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M |
| Gross profit | $97.3M | $81.5M | $73.4M | $56.7M |
| Operating income | -$124.9M | -$96.8M | -$65.5M | -$79.0M |
| Net income | -$153.5M | -$126.9M | -$102.2M | -$109.8M |
| Operating cash flow | -$162.4M | -$96.8M | -$76.4M | -$87.6M |
| Cash | $110.7M | $172.0M | $95.0M | $55.4M |
| Long-term debt | $122.2M | $121.7M | $98.6M | $97.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
URGN Stock Sonar score 6/7 axes
Find similar shapesCompareURGN ranks highest on growth (68th percentile) and profitability (56th), and lowest on insider conviction (10th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
URGN filings, in plain words
Are UroGen Pharma insiders buying or selling URGN?
In the 180 days to 2026-10-28, UroGen Pharma insiders were net sellers, a net $4.2M across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of URGN?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $3.1M of stock; the latest, by Christopher Degnan, was filed 2026-10-09.
Read the full summary
In the 180 days to 2026-10-28, UroGen Pharma insiders were net sellers of URGN, a net $4.2M across purchases and sales reported on Form 4 by 3 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $3.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
